• To study the effect of sulindac on the alteration of the blood-retinal barrier, 24 insulin-dependent diabetic patients with minimal or no retinopathy were randomly assigned to receive either oral sulindac (200 mg twice daily) or a placebo for a period of six months. All patients underwent fundus photography, fluorescein angiography, and vitreous fluorophotometry before treatment and after 1, 3, and 6 months of treatment. Vitreous fluorophotometry data showed that there were fewer alterations of the blood-retinal barrier in the sulindac group compared with the placebo group during the six-month study period.
Cunha-Vaz JG, Mota CC, Leite EC, Abreu JR, Ruas MA. Effect of Sulindac on the Permeability of the Blood-Retinal Barrier in Early Diabetic Retinopathy. Arch Ophthalmol. 1985;103(9):1307–1311. doi:10.1001/archopht.1985.01050090059032
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.